News coverage about uniQure N.V. (NASDAQ:QURE) has trended positive this week, AlphaOne reports. The research group, a service of Accern, scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. uniQure N.V. earned a news sentiment score of 0.31 on AlphaOne’s scale. AlphaOne also gave media stories about the biotechnology company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the company’s share price in the near term.
These are some of the media stories that may have impacted AlphaOne Sentiment Analysis’s analysis:
- uniQure Publishes Data Further Demonstrating Favorable Immunogenicity Profile and Broad Utilization of AAV5-Based … – Nasdaq (nasdaq.com)
- Form 8-K uniQure NV For: Jun 14 – StreetInsider.com (streetinsider.com)
- UNIQURE N.V. : Submission of Matters to a Vote of Security Holders (form 8-K) (4-traders.com)
- uniQure Publishes Data Further Demonstrating Favorable Immunogenicity Profile and Broad Utilization of AAV5-Based Gene Therapies (finance.yahoo.com)
- A Run Through Uniqure NV (QURE)’s Technicals – Hayden Business Journal (haydenbusinessjournal.com)
Shares of uniQure N.V. (QURE) traded down 2.72% during trading on Friday, hitting $5.00. The stock had a trading volume of 125,514 shares. The stock’s 50 day moving average is $5.27 and its 200-day moving average is $5.73. uniQure N.V. has a 12-month low of $4.72 and a 12-month high of $9.72. The company’s market cap is $127.22 million.
uniQure N.V. (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.80) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.64) by $0.16. The business had revenue of $3.32 million during the quarter, compared to analysts’ expectations of $4.20 million. uniQure N.V. had a negative net margin of 223.38% and a negative return on equity of 103.26%. Analysts forecast that uniQure N.V. will post ($3.39) earnings per share for the current year.
QURE has been the topic of a number of recent research reports. Cowen and Company reissued a “buy” rating on shares of uniQure N.V. in a research note on Wednesday, May 24th. Oppenheimer Holdings, Inc. set a $17.00 price objective on uniQure N.V. and gave the stock a “buy” rating in a research note on Tuesday, May 16th. Jefferies Group LLC reissued a “hold” rating and set a $8.00 price objective on shares of uniQure N.V. in a research note on Wednesday, April 12th. Zacks Investment Research lowered uniQure N.V. from a “buy” rating to a “sell” rating in a research note on Wednesday, May 17th. Finally, ValuEngine lowered uniQure N.V. from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $15.28.
About uniQure N.V.
uniQure N.V. (uniQure) is a gene therapy company. The Company is engaged in developing single treatments with curative results for patients suffering from genetic and other severe diseases. The Company is advancing a focused pipeline of gene therapies that have been developed both internally and through partnerships.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.